Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PASSPoRT: Personalized Antiplatelet Secondary Stroke Prevention
NCT03979781Phase 2Completed
- Sponsor
- Upstate Medical University
- Start
- Jun 2018
- Primary completion
- May 2023
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in ischemic stroke and Transient Ischemic Attack (TIA) (2 arms), sponsored by Upstate Medical University. Primary endpoints: Feasibility - Recruitment and Platelet Reactivity at 90 days and Safety - Bleeding Complications at 1 year. Started Jun 2018; status: completed.
02
Conditions
ischemic strokeTransient Ischemic Attack (TIA)
Beyond the preview
Go deeper on NCT03979781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03979781.